Clinical Trials
38 trialsA Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
NOM-ERA
Washington University School of Medicine
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Canadian Cancer Trials Group
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
Jiangsu HengRui Medicine Co., Ltd.
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Big Ten Cancer Research Consortium
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Stanford University
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Henry Ford Health System
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Canadian Cancer Trials Group
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Amgen
Study of Vitamin D in Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Lidocaine for Oxaliplatin-induced Neuropathy
Washington University School of Medicine
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
COLOPEC
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
DEBIRI
University of Louisville
Sequoia
Eli Lilly and Company
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Brown University
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
SIRFLOX
Sirtex Medical
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Radiation Therapy Oncology Group
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
HORIZON III
AstraZeneca
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
University of Utah
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
H. Lee Moffitt Cancer Center and Research Institute
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
HORIZON II
AstraZeneca
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
SCRI Development Innovations, LLC
Phase 3 Trial of Litxâ„¢ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
Light Sciences Oncology
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
APEC
Merck KGaA, Darmstadt, Germany
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Yale University
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
AstraZeneca
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Hoffmann-La Roche